




#KeepYourThyroid #DesignedToPredictBenign

The Thyroid Genetic Classifier to safely forgo unnecessary diagnostic thyroid surgery for indeterminate cytology

Up to 20% of thyroid nodule FNA biopsies are reported as indeterminate (Bethesda III/IV) following cytological examination. These nodules are managed through diagnostic surgery which is the standard approach. After surgery, up to 75% of these nodules are determined to be benign.¹ ThyroidPrint[®] reclassifies nodules as either benign or suspicious of malignancy, aiding decision-making, avoiding patients to undergo unnecessary surgeries, and reducing healthcare costs.

ThyroidPrint[®] clinical pathway in case of thyroid nodule detection

ThyroidPrint[®] accurately classifies indeterminate thyroid nodules with 95% NPV^{2,3}




ThyroidPrint[®] Clinical Utility Study reduces unnecessary surgery by 67%⁴

Without ThyroidPrint[®]



With ThyroidPrint[®]



Idylla™ ThyroidPrint® Assay**

First-in-class cartridge-based assay for risk stratification of indeterminate thyroid nodules
 For Research Use Only, not for use in diagnostic procedures

Idylla™ ThyroidPrint® Assay**



qPCR
of 10 genes

Proprietary algorithm analysis

Idylla™ ThyroidPrint® Result
reported as either 'HIGH' or 'LOW'

CXCR3, CXCL10, CCR3, CCR7, CXADR

TIMP1, CLDN1, KRT19, AFAP1L2, HMOX1

Tumor Inflammatory Microenvironment Genes

Tumor Epithelial Genes



Unique sample-to-insight seamless workflow



Scan Sample & Cartridge



Insert Sample in the Cartridge



Insert Cartridge in the Idylla™ Platform and obtain the result within 3 hours

- (1) Haugen et al., 2015 American Thyroid Association Management guidelines for adult patients. *Thyroid*, 2016
- (2) Gonzalez et al., A 10-Genes Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study. *Thyroid*, 2017
- (3) Zafereo et al., A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. *Thyroid*, 2020
- (4) Olmos et al., ThyroidPrint®: clinical utility for indeterminate thyroid cytology. *End Rel Cancer*, 2023

thyroidprint.com



Biocartis NV
 Generaal De Wittelaan 11B
 2800 Mechelen - Belgium
 +32 15 632 888

Follow us on

www.biocartis.com
customerservice@biocartis.com

*ThyroidPrint® LDT currently available as a Laboratory Developed Test in GeneproDx' CAP accredited laboratory in Santiago de Chile (Chile).
 **Idylla™ ThyroidPrint Assay is for Research Use Only (RUO), not for use in diagnostic procedures, developed by GeneproDX and distributed by Biocartis. ©February 2025, Biocartis NV. All rights reserved.